Literature DB >> 6115478

Parathyroid "double adenomas": fact of fiction?

C A Verdonk, A J Edis.   

Abstract

It has been suggested that primary hyperparathyroidism (HPT) may occasionally be caused by "multiple adenomas." If this is true, then selective excision of the enlarged glands should be curative in such cases. To examine this proposition, we reviewed the records of 1,962 patients with surgically proved HPT and culled all those who met the following criteria: (1) identification and excision of two enlarged and histologically hypercellular parathyroid glands, each weighing more than 70 mg, and (2) identification and preservation of two other normal-sized parathyroid glands. There were 38 such patients (1.9% of the total group). Thirty-seven patients were euparathyroid at follow-up (an average of 4.6 years postoperatively). Only one individual, a member of a kindred with multiple endocrine neoplasia (MEN), type 1, had persistent HPT; but four other patients with MEN syndromes were among the group cured by surgery. The findings of this study support the notion that more than one adenoma may occasionally be found in primary HPT, and that selective excision of the enlarged glands with preservation of the normal parathyroid glands constitutes adequate treatment. One possible exception to this rule is the patient with either familial HPT or one of the MEN syndromes; subtotal parathyroidectomy is preferred in this situation.

Entities:  

Mesh:

Year:  1981        PMID: 6115478

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  10 in total

1.  Identification of somatic mutations in parathyroid tumors using whole-exome sequencing.

Authors:  M Kyle Cromer; Lee F Starker; Murim Choi; Robert Udelsman; Carol Nelson-Williams; Richard P Lifton; Tobias Carling
Journal:  J Clin Endocrinol Metab       Date:  2012-06-27       Impact factor: 5.958

Review 2.  Primary hyperparathyroidism in the 1990s. Choice of surgical procedures for this disease.

Authors:  E L Kaplan; T Yashiro; G Salti
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

3.  [Cystic parathyroid gland adenomas: pathologic-anatomic variants of parathyroid gland adenomas or a separate disease entity?].

Authors:  C Nies; C Hasse; A Zielke; P K Wagner; M Rothmund
Journal:  Langenbecks Arch Chir       Date:  1992

4.  Cost-effectiveness of preoperative localization studies in primary hyperparathyroid disease.

Authors:  S M Roe; R P Burns; L D Graham; W B Brock; W L Russell
Journal:  Ann Surg       Date:  1994-05       Impact factor: 12.969

5.  Molecular classification of parathyroid neoplasia by gene expression profiling.

Authors:  Carl Morrison; William Farrar; Jeff Kneile; Nita Williams; Yiwen Liu-Stratton; Alan Bakaletz; Micheala A Aldred; Charis Eng
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

6.  Scan-directed unilateral cervical exploration for parathyroid adenoma: a legitimate approach?

Authors:  C F Russell; J D Laird; W R Ferguson
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

7.  Hyperparathyroidism associated with the enlargement of two or three parathyroid glands.

Authors:  S A Wells; G S Leight; M Hensley; W G Dilley
Journal:  Ann Surg       Date:  1985-11       Impact factor: 12.969

Review 8.  Unilateral neck exploration for primary hyperparathyroidism: analysis of a controversy using a mathematical model.

Authors:  Q Y Duh; P Udén; O H Clark
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

Review 9.  Primary hyperparathyroidism in younger and older patients: symptoms and outcome of surgery.

Authors:  P Udén; A Chan; Q Y Duh; A Siperstein; O H Clark
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

10.  Evidence of a stabilizing mutation of β-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas.

Authors:  Lee F Starker; Annabelle L Fonseca; Annabelle Fonseca; Göran Akerström; Peyman Björklund; Gunnar Westin; Tobias Carling
Journal:  Endocrine       Date:  2012-05-11       Impact factor: 3.633

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.